Quinine for night-time leg cramps no longer recommended
Last reviewed: December 2009
Quinine for nighttime leg cramps? Think again
If you have nocturnal (nighttime) leg cramps, your doctor might prescribe quinine (Qualaquin)-even though the U.S. Food and
Drug Administration has approved it for only one purpose: to treat malaria (although doctors can legally prescribe most medications
for any type of treatment they deem appropriate).
Leg cramps are uncontrolled muscle contractions that can be so painful they can waken you from sleep. They occur in many adults
and are reported more often by women, and especially pregnant women.
Since the 1940s, doctors have been prescribing quinine for leg cramps because there are no other reliable treatments. The
practice has continued despite multiple alerts from the FDA about the risks of quinine and its limited effectiveness.
Prescribing remains high despite warnings
The FDA has issued warnings about quinine since 1994 and more recently about its minimal effectiveness in treating leg cramps.
In 2006, it banned the sale of all unapproved drugs that contained quinine except the branded drug, Qualaquin, because of
the risk of serious side effects or death. Yet in the first six months of 2008, more than 124,000 people in the U.S. received
close to 300,000 prescriptions for Qualaquin, according to the FDA. Since the Centers for Disease Control and Prevention reports
that only about 1,500 individuals were diagnosed with malaria last year, it appears that quinine is still frequently prescribed
off-label.
Indeed, from January 2006 to June 2008, 62 percent of Qualaquin prescriptions were for musculoskeletal symptoms, mainly for
nocturnal leg cramps. Of the 38 reports of serious adverse events received by the FDA in roughly the same time period, over
half (55 percent) were from people who had taken quinine for leg cramps.
This off-label drug use report is made possible through a collaboration between Consumer Reports Best Buy Drugs and the American
Society of Health-System Pharmacists. This is the eighth in a series based on professional reports prepared by ASHP.
These materials were made possible by a grant from the state Attorney General Consumer and Prescriber Education Grant Program,
which is funded by a multistate settlement of consumer fraud claims regarding the marketing of the prescription drug Neurontin
(gabapentin).